AstraZeneca Plc has announced two new deals in immuno-oncology that will exploit the potential of its checkpoint inhibitor MED14736 in both haematological and solid tumour cancers. The monoclonal antibody is currently in Phase 3 development for non-small cell lung cancer and head and neck cancer.
